Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Immunoglobulin A nephropathy (IgAN), the most common primary glomerular disease worldwide, is a leading cause of end-stage renal disease. However, effective treatment options remain limited for refractory IgAN patients with stage CKD 4.
This paper reports the case of a 33-year-old female patient with a 16-year history of IgAN. Despite long-term treatment with glucocorticoids, angiotensin-converting enzyme inhibitor and immunosuppressants, she had persistent moderate to severe proteinuria and exhibited progressive increase in serum creatinine (Scr). A repeat renal biopsy indicated "IgA nephropathy with 7/10 global glomerulosclerosis," classified as M1E1S1T2C0. Subsequently, a combination regimen of Telitacicept (80mg QW), glucocorticoids and immunosuppressants(tacrolimus and hydroxychloroquine) was initiated.During follow-up,prednisone dose was tapered and subsequently discontinued. Over the 26-month follow-up period, the data of this patient, including estimated glomerular ffltration rate (eGFR), 24-hour urinary protein quantification(24hUTP), Scr and albumin(ALB), were collected longitudinally and analyzed.
During the 26-month follow-up, the patient's urinary protein significantly decreased from a baseline of 3.60g/24h to 1.15g/24h at 1 month and continued to decrease to 0.07g/24h at 26 months. The levels of Scr, despite some fulctuations, exhibited an overall downward trend (from a baseline of 342.8umol/L to 250.3umol/L at 26 months). Correspondingly, her estimated glomerular filtration rate(eGFR) showed an overall upward trend with a total slope of +2.1 ml/min/1.73m² per year. Serum albumin remained within the normal range throughout. During the treatment period, the patient experienced only a mild upper respiratory tract infection, with no occurrence of severe infections or other serious complications.
This case demonstrates that treatment with Telitacicept combined with glucocorticoid and immunosuppressants can significantly reduce proteinuria, improve renal function and successfully delay dialysis initiation for at least 26 months, providing a safe and effective treatment strategy for refractory IgAN patients with stage CKD 4. In addition, it also underscores the critical value of active proteinuria in preserving renal function, even in this advanced disease stage.
